期刊文献+

Cortactin Overexpression Correlates with Poor Prognosis in Hepatocellular Carcinoma 被引量:1

Cortactin Overexpression Correlates with Poor Prognosis in Hepatocellular Carcinoma
暂未订购
导出
摘要 Objective: To investigate cortactin expression in hepatocellular carcinoma (HCC) and explore its significance in the prognosis of HCC patients. Methods: Immunohistochemistry was performed for paraffin samples of 119 pairs of HCC tissues (HCCs) and paratumorous liver tissues (PTLTs) to evaluate cortactin expression. The cortactin expression difference in HCCs and PTLTs were analyzed by the McNemar's test. The relationship of cortactin expressions in HCCs and clinicopathologic factors was analyzed with Mann-Whitney U test. The Kaplan-Meier method and log-rank test were employed to compare the overall survival between Cortactin negative expression group, weak expression group and strong expression group. Expression of cortactin was further determined in 19 pairs of fresh HCCs and PTLTs specimens with Western blotting. Results: Cortactin expression rate was significantly higher in HCCs (53/119, 44.5%) than that in PTLTs (2/119, 1.7%) (P〈0.001). The upregulated cortactin expression in HCCs was significantly correlated to absence of capsule formation (P=0.012), vascular invasion (P=0.037) and high Edmondson-Steiner grade (P=0.020), and predicted shorter overall survival. Western blotting demonstrated that cortactin expression was upregulated in 9 out of 19 HCCs (47.4%) compared to corresponding PTLTs. Conclusion: Cortactin expression is upregulated in HCC and is related to shorter overall survival of patients, suggesting that cortactin might play roles in the metastasis of HCC and predict a poor prognosis of HCC patients. Objective: To investigate cortactin expression in hepatocellular carcinoma (HCC) and explore its significance in the prognosis of HCC patients. Methods: Immunohistochemistry was performed for paraffin samples of 119 pairs of HCC tissues (HCCs) and paratumorous liver tissues (PTLTs) to evaluate cortactin expression. The cortactin expression difference in HCCs and PTLTs were analyzed by the McNemar's test. The relationship of cortactin expressions in HCCs and clinicopathologic factors was analyzed with Mann-Whitney U test. The Kaplan-Meier method and log-rank test were employed to compare the overall survival between Cortactin negative expression group, weak expression group and strong expression group. Expression of cortactin was further determined in 19 pairs of fresh HCCs and PTLTs specimens with Western blotting. Results: Cortactin expression rate was significantly higher in HCCs (53/119, 44.5%) than that in PTLTs (2/119, 1.7%) (P〈0.001). The upregulated cortactin expression in HCCs was significantly correlated to absence of capsule formation (P=0.012), vascular invasion (P=0.037) and high Edmondson-Steiner grade (P=0.020), and predicted shorter overall survival. Western blotting demonstrated that cortactin expression was upregulated in 9 out of 19 HCCs (47.4%) compared to corresponding PTLTs. Conclusion: Cortactin expression is upregulated in HCC and is related to shorter overall survival of patients, suggesting that cortactin might play roles in the metastasis of HCC and predict a poor prognosis of HCC patients.
出处 《Chinese Journal of Cancer Research》 SCIE CAS CSCD 2010年第2期112-118,共7页 中国癌症研究(英文版)
基金 supported by grants from the National"863"High Technology Research and Development Program of China(No.2006AA02A308) the Beijing Municipal Key Project(No.H030230280410) by a grant from the National Key Technologies R&D Program of China(No.2008ZX 10002-016)
关键词 Hepatoeellular carcinoma (HCC) CARCINOGENESIS Prognosis CORTACTIN Hepatoeellular carcinoma (HCC) Carcinogenesis Prognosis Cortactin
  • 相关文献

参考文献2

二级参考文献22

  • 1谢海龙,周晓军,陈洁宇,黄文斌,张丽华,李芳秋.胃癌癌变相关基因表达的cDNA微阵列研究[J].临床与实验病理学杂志,2005,21(2):137-141. 被引量:5
  • 2Bringuier PP, Tamimi Y, Schuuring E, et al. Expression of cyclin D1 and EMS1 in bladder tumours; relationship with chromosome 11q13 amplification. Oncogene, 1996,12:1747-1753.
  • 3Scully C, Field JK, Tanzawa H. Genetic aberrations in oral or head and neck squamous cell carcinoma (SCCHN):1.Carcinogen metabolism, DNA repair and cell cycle control. Oral Oncol, 2000, 36:256-263.
  • 4Liu SC, Klein-Szanto AJ. Markers of proliferation in normal and leukoplakic oral epithelia. Oral Oncol, 2000, 36:145-151.
  • 5Huang X, Gollin SM, Raja S, et al. High-resolution mapping of the 11q13 amplicon and identification of a gene, TAOS1, that is amplified and overexpressed in oral cancer cells. Proc Natl Acad Sci U S A, 2002, 99:11369-11374.
  • 6Schuuring E, van Damme H, Schuuring-Scholtes E, et al. Characterization of the EMS1 gene and its product, human Cortactin. Cell Adhes Commun, 1998, 6:185-209.
  • 7Rodrigo JP, Garcia LA, Ramos S, et al. EMS1 gene amplification correlates with poor prognosis in squamous cell carcinomas of the head and neck. Clin Cancer Res, 2000, 6:3177-3182.
  • 8Schuuring E, Verhoeven E, van Tinteren H, et al. Amplification of genes within the chromosome 11q13 region is indicative of poor prognosis in patients with operable breast cancer. Cancer Res, 1992, 52: 5229-5234.
  • 9Patel AM, Incognito LS, Schechter GL, et al.Amplification and expression of EMS-1 (cortactin) in head and neck squamous cell carcinoma cell lines. Oncogene, 1996, 12: 31-35.
  • 10Ormandy C J, Musgrove E A, Hui R, et al. Cyclin D1, EMS1 and 11q13 amplification in breast cancer [J]. Breast Cancer Res Treat, 2003,78 (3) : 323-335.

共引文献4

同被引文献3

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部